Determining Minimal Residual Disease Using ctDNA Deep Sequencing
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorMasaryk Memorial Cancer Institute
About this trial
Preoperative neoadjuvant chemotherapy is the standard treatment for locally advanced gastrointestinal tumours. However, not all patients respond to preoperative treatment. Early identification of progression during neoadjuvant chemotherapy or diagnosis of early disease relapse during adjuvant treatment is essential to modify the treatment strategy. The aim of this project is to validate ctDNA as a biomarker of molecular relapse/progression of disease.
Eligibility criteria
Qualifiers
Consent to participate in the study
Patients with esophageal, gastric, or pancreatic cancer, stage 0-2
Patients with locally advanced, potentially operable disease treated with systemic perioperative chemotherapy or chemoradiotherapy
Patients with metastatic disease treated with first- to third-line palliative systemic therapy
Disqualifiers
not specified
Trial design
Treatments tested in this trial
- NGS sequencing of mutations selected based on sequencing of primary tumors
Treatment groups
34 Participants
are divided into 2 treatment groupsLocations
1Masaryk Memorial Cancer Institute65653, Brno Czechia
Sponsors and collaborators
Masaryk Memorial Cancer Institute
Lead sponsor
Source ClinicalTrials.gov